Overview

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborators:

Astellas Pharma Inc
Medivation is now a wholly owned subsidiary of Pfizer Inc.
Medivation, Inc.

Treatments:

Estrogens
Exemestane
Progesterone